Beta-Caryophyllene

SMITHS FALLS, ON, Jan. 24, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC), a world-leading diversified cannabis company, today announced the introduction of new product offerings across the Company's adult use and medical cannabis portfolio, including new Tweed softgels and oils featuring minor cannabinoids, a large format flower offering from Tweed, as well as new medical exclusive pre-roll products from 7ACRES and Spectrum Therapeutics. "In addition to launching new flower products, we're making it easier to access CBD and minor cannabinoids in convenient oil and softgel formats to support wellness-minded consumers looking to start the year feeling their best," said Dave Paterson, President, Canada, Canopy Growth. "For our medical cannabis consumers, we're proud to continue delivering the variety and convenience that the Spectrum Therapeutics store is synonymous for thanks to new pre-rolls from 7ACRES and the Spectrum Reserve." Tweed Lemon Meringue Pie flower For consumers not wanting to compromise quality for quantity, Tweed Lemon Meringue Pie is being served up fresh in a large format 28g package. Packed with sativa whole cannabis flower which has been derived from the Lemon Skunk and Cookies 'n' Cream lineage, it features terpenes a-Pinene, Myrcene and Limonene. Tweed's Lemon Meringue Pie boasts lemon, citrus and nutty vanilla aromas, is hang-dried, and comes in with a 23-29% THC range. Grown in our Kincardine, Ontario facility and packaged with a Boveda humidity control pack to ensure freshness, this new flower offering is full of flavour just like lemon meringue should be. 7ACRES Jack Haze pre-rolls 7ACRES Jack Haze pre-rolled joints are arriving in a 0.5gx14 large pack and feature the famous sativa-dominant cultivar with a unique combination of sweet citrus, crisp pine, and warm spice notes. With a range of 17-23% THC and a max CBD potency of 25%, 7ACRES Jack Haze was the result of a large-scale genetic selection program with the goal of finding this novel sativa expression. This phenotype stood out among the rest as it possessed both the sweet haze notes characteristic of a haze cultivar, along with a distinct spice aroma. Spectrum Reserve pre-rolls Exclusive for medical cannabis customers, Spectrum Therapeutics is extending its Spectrum Reserve collection with Alien Breath and (GG#4 x Mendo Breath) pre-roll joints. Coming in a 0.5gx10 large pack of pre-rolls, this hybrid strain delivers a high 22-28% THC range. The flower's berry, fruity, nutty, sour, and chemical notes derive from its Alien Breath and (GG#4 x Mendo Breath) lineage and its terpenes include 3.5% β-Caryophyllene, 6% D-Limonene, 6.5% Beta Myrcene, and 10% Pinene (Alpha & Beta). With consumer needs top of mind, Tweed has also introduced four new products featuring CBD and minor cannabinoids in both oil and softgel formats. Tweed CBD:CBG 4:1 Oil A newly formulated cannabis oil arriving in a 30mL bottle, Tweed CBD:CBG 4:1 is designed to pair with well-being focused daily routines and provides 100 mg/g CBD and 25 mg/g CBG. Tweed CBD:CBG 6:1 Softgels For those who prefer the convenience and portability of the softgel format, Tweed CBD:CBG 6:1 is available with 30 softgels per bottle each containing 60 mg of CBD and 10 mg CBG. Tweed CBD:CBN 4:1 Oil Coming in a 30mL oil format, the Tweed CBD:CBN 4:1 oil offering is designed to become part of a nightly routine and delivers 100 mg/g CBD and 25 mg/g CBN. Tweed CBD:CBN 6:1 Softgels Another win for those who prefer the convenience of softgels, Tweed CBD:CBN 6:1 is available with 30 softgels per bottle each containing 60 mg of CBD and 10 mg CBN. Tweed oil and softgel products are made with non-GMO, coconut derived MCT oil and blended cannabis extracts. All Tweed offerings are available for purchase via legal recreational cannabis e-commerce channels and retail locations in select regions. 7ACRES and Spectrum products are available for purchase online at spectrumtherapeutics.com. For more information, please visit Tweed and Spectrum Therapeutics. Disclaimer: Terpene amounts may vary on a per-lot basis due to the natural variability of cannabis plants. THC and CBD ranges may vary. See product packaging for accurate levels. Everyone experiences cannabis differently. About Canopy Growth Canopy Growth is a leading North American cannabis and consumer packaged goods ("CPG") company dedicated to unleashing the power of cannabis to improve lives. Through an unwavering commitment to our consumers, Canopy Growth delivers innovative products with a focus on premium and mainstream cannabis brands including Doja, 7ACRES, Tweed, and Deep Space. Canopy Growth's CPG portfolio includes gourmet wellness products by Martha Stewart CBD, and category defining vaporizer technology made in Germany by Storz & Bickel. Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through its rights to Acreage Holdings, Inc., a vertically integrated multi-state cannabis operator with principal operations in densely populated states across the Northeast, as well as Wana Brands, a leading cannabis edible brand in North America, and Jetty Extracts, a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology. Beyond our world-class products, Canopy Growth is leading the industry forward through a commitment to social equity, responsible use, and community reinvestment—pioneering a future where cannabis is understood and welcomed for its potential to help achieve greater wellbeing and life enhancement. For more information visit References to information included on, or accessible through, our website do not constitute incorporation by reference of the information contained at or available through our website, and you should not consider such information to be part of this press release. SOURCE Canopy Growth Corporation

The real-world evidence study will be conducted in Montreal, Quebec, with Santé Cannabis and will evaluate the efficacy of the product on patients with musculoskeletal pain and inflammationTORONTO, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial stage, international biopharmaceutical company focused on the commercialization of evidence-based, cannabinoid-based products, is pleased to announce that it will be initiating an observational real-world evidence (“RWE”) study using RHO Phyto branded Cannabigerol (“CBG”) transdermal gel on patients with musculoskeletal pain and inflammation together with Santé Cannabis, a clinical research site (“CRS”) and contract research organization (“CRO”). Observational Real-World Evidence Study The research study will seek to enroll 100 patients and evaluate patient-reported efficacy of the RHO Phyto CBG Transdermal Gel containing 2% Cannabidiol (“CBD”) and 1% CBG on arthritis including osteoarthritis, rheumatoid arthritis, fibromyalgia, muscle and/or joint pain, localized pain, post-surgical pain, muscular and/or structural injuries. The participants, as identified by the healthcare provider will take part in a 3-month study including clinical visits at baseline and 3-month follow-up assessment. In addition to demographic, medical history, medication use and overall symptom assessment questionnaires, the patients will complete the Musculoskeletal Health Questionnaire, a validated measure of symptoms and quality of life. The study will be conducted by Santé Cannabis, an independent medical cannabis clinic and research services provider. Santé Cannabis has developed a data collection platform and centred model in executing upon its role as a CRS and CRO. The prospective study is expected to launch in early Q1 2023. ‘’The exploration of novel topical formulations is very exciting to our clinical team as products may provide patients with localized pain relief while avoiding systemic effects and side effects all together’’ states Dr. Michael Dworkind, Medical Director of Santé Cannabis and Associate Professor of McGill University. “We are so pleased to work with Avicanna to assess the effectiveness of their RHO Phyto CBG Transdermal Gel, to shed light on the very understudied field of cannabinoid-based topical products.” Dr. Karolina Urban, Vice President of Scientific and Medical Affairs stated: “We are happy to partner with Santé Cannabis, which has built a comprehensive registry database for conducting real-world evidence studies. With the initiation of the study, we will further demonstrate our ongoing dedication to researching, developing, and making available evidence-based products to patients and the medical community.” RHO Phyto Transdermal CBG Gel The CBG Transdermal Gel is a part of Avicanna’s RHO Phyto formulary of medical products which includes proprietary oral, sublingual, and topical products containing a range of cannabinoids. The gel includes a combination of CBG and CBD in a fast-absorbing, water-based gel intended for application locally to area of focus. The gel utilizes Avicanna’s deep tissue emulsion technology and combines cannabinoids with synergistic natural ingredients and terpenes including menthol, eugenol and beta-caryophyllene. ABOUT SANTÉ CANNABIS SANTÉ CANNABIS IS CANADA’S MEDICAL CANNABIS CENTRE OF EXCELLENCE: An independent medical cannabis clinic and clinical practice leader driving research services and healthcare professional training to improve practical knowledge of cannabis-based medicines. Established in 2014, Santé Cannabis has defined medical cannabis patient care and clinical data collection in Canada within a multidisciplinary, patient-centred model of care. The team of physicians and nurses at Santé Cannabis has supported more than 16,000 patients referred by 6,000 unique physicians across the province of Quebec, providing an innovative, integrated, community-based consult service for cannabis-based medicines. Recognized internationally as being at the forefront of medical cannabis, Santé Cannabis aims to share the expertise of its team of innovators, healthcare professionals, researchers and support personnel through collaborative networks to support clinic development and clinical research services from strategy and product development consultation to clinical trial recruitment and real-world data processes. ABOUT AVICANNA INC. Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments: Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training. Pharmaceutical Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders. Avicanna’s first pharmaceutical preparation (Trunerox™) is in the drug registration stage in South America. Click to watch Avicanna’s Corporate Video 2022 SOURCE Avicanna Inc. Stay Connected For more information about Avicanna, visit www.avicanna.com, contact Ivana Maric by email at info@avicanna.com or follow us on social media on LinkedIn, Twitter, Facebook or Instagram. The Company posts updates through videos from the official Company YouTube channel. Cautionary Note Regarding Forward-Looking Information and Statements This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of the proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company’s future business operations, potential collaborations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated March 31, 2022, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b23c8a9b-c271-4c73-b966-3e83b244ddc6